HOME >> BIOLOGY >> NEWS
Wistar immunologists awarded grants to promote the development of vaccinesagainst HIV-1 and human papilloma viruses

Philadelphia -- Three Wistar Institute immunologists have been awarded grants to support their development of vaccines against diseases that attack the mucous membranes. Principal Investigator, Hildegund Ertl, MD, was awarded a grant by the Mary L. Smith Charitable Lead Trust for her research on HIV-1 vaccines. Anthony Wlazlo, PhD, and Dariusz Kowalczyk, MD, researchers in Dr. Ertl's laboratory, earned fellowships from the Cancer Research Foundation of America for their development of vaccines against human papilloma viruses (HPV).

Because the mucous membranes are protected by an independent immune system, Dr. Ertl suspects they are not adequately protected by systemic vaccines. Consequently, she and her Wistar research team are designing vaccines that target the mucosal immune system.

To successfully prevent HIV-1, explains Dr. Ertl, a combination vaccine is needed to induce neutralizing antibodies at the site of virus entry, usually the genital mucosa, and to trigger the production of killer T cells. Immunologists have yet to determine if it is possible to do both simultaneously. The immune system typically generates either a Th1 response to disease, which activates killer T cells, or a Th2 response, which promotes the development of B cells that secrete antibodies at mucosal surfaces. It is a challenge, says Dr. Ertl, to develop a vaccine that can simultaneously induce both. Dr. Ertl's findings will also be useful to scientists in other research centers exploring similar approaches

At the same time, other scientists in Dr. Ertl's laboratory are developing vaccines against HPV, a group of viruses known to cause cervical cancer, the second most common malignancy in women. Rather than treating the cancer, explains Dr. Ertl, the key to controlling HPV is through a vaccine that prevents the infection. The researchers' goal is to produce a strong and enduring mucosal immunity by neutralizing antibodies that, in model systems, prevent infection
'"/>

Contact: Diana Cutshall
dcutshall@wistar.upenn.edu
215-898-3716
The Wistar Institute
6-Jul-1999


Page: 1 2

Related biology news :

1. Wistar-discovered antibody will help diagnose appendicitis
2. 2004 Wistar Institute Science Journalism Award winners announced
3. Call for Entries: The 2004 Wistar Institute Science Journalism Award
4. Wistar-developed antibody shows promise against brain tumors in Drexel trial
5. Wistar study offers new support for a histone code theory of gene regulation
6. Regeneration in the mammalian heart demonstrated by Wistar researchers
7. Wistar scientists add difficult-to-sequence stretches to human genome data
8. Wistar scientist receives award from National Cancer Institute
9. Director of Emory Vaccine Center to give Wistar Institutes 1999 Tadeusz J. Wiktor Memorial lecture
10. Wistar scientists find striking similarities between bacterial virus and human adenovirus
11. Wistar Institute scientists find key piece in gene regulation puzzle

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/1/2019)... FRANCISCO (PRWEB) , ... April 01, 2019 , ... ... “Method and System for Characterizing Skin Related Conditions” by the US Patent and ... 2014. The patent is an invention by uBiome collaborators Dr. Zachary Apte, ...
(Date:3/29/2019)... ... March 28, 2019 , ... In the wake of the ... dedicated to Chinese biobanks was launched in July 2018, in an agreement between ... Branch, China Medicinal Biotech Association (BBCMBA). The one-year pilot programme offered two testing ...
(Date:3/29/2019)... ... March 29, 2019 , ... GenCure has selected G-CON ... therapy facility. The new facility, which will anchor the VelocityTX innovation center in ... art manufacturing capabilities to support clinical cell therapy trials. GenCure is a subsidiary ...
Breaking Biology News(10 mins):
(Date:4/8/2019)... ... April 09, 2019 , ... To support the global ... Zuckerberg Biohub (CZ Biohub) has chosen Geneious Biologics to help them analyze and ... Biohub’s efforts to establish new approaches to inform the discovery of antibody-based diagnostics, ...
(Date:4/4/2019)... ... April 03, 2019 , ... ... intimate off-the-record collaboration and dialogue, today announces its Boston CEO conference to be ... into the industry’s challenges and opportunities with high-level panels and discussions from past, ...
(Date:3/27/2019)... ... , ... A leader in the field of Regenerative Veterinary Medicine, VetStem Biopharma ... and Canada since 2004. The primary indications for VetStem Regenerative Cell Therapy are ... cat, and horse. Recently, VetStem teamed up with the world-renowned San Diego Zoo ...
(Date:3/27/2019)... ... ... Lachman is sponsoring the event on April 1-4, where they will be located ... on site will be available to discuss strategies and tactics to support Facilities of ... Executives from Lachman participating at this year’s conference include Fran Zipp, President & CEO, ...
Breaking Biology Technology:
Cached News: